SAN DIEGO--(BUSINESS WIRE)--Samumed, a leader in Wnt research and development, has been selected for an oral presentation at the 2017 Gordon Research Conference, “Wnt Signaling: A Pathway Implicated in Animal Development, Stem Cell Control and Cancer,” to be held in Stowe, Vermont on August 6-11, 2017.
“We are excited to be presenting at the prestigious Gordon Research Conference, which provides an international forum for the discussion of cutting-edge research in life sciences,” said Dr. Yusuf Yazici, Samumed’s Chief Medical Officer. “The preclinical research that formed the basis of our promising investigational drug for the treatment of osteoarthritis is an example of how innovative science can translate into clinical benefit.”
Samumed’s presentation, “Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis,” will be available on the company website after the conference at: http://bit.ly/2hhTp68.
About Gordon Research Conferences
Gordon Research Conferences is an organization that coordinates renowned international scientific conferences dedicated to advancing the frontiers of scientific research in the biological, chemical, and physical sciences, and their related technologies. To attend a meeting, scientists must apply to that respective research conference. The conference chair carefully considers every applicant and hand-selects 200 attendees for each conference. Further information can be found at: https://www.grc.org.
About Samumed, LLC
Based in San Diego, CA, Samumed (www.samumed.com) is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation. Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.
For Samumed
Chrissy Randall, 202-393-7337
crandall@brunswickgroup.com
